Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Immunotherapy"" wg kryterium: Temat


Tytuł :
Human chimeric antigen receptor macrophages for cancer immunotherapy.
Autorzy :
Klichinsky M; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; Carisma Therapeutics, Philadelphia, PA, USA.
Ruella M; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Shestova O; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Lu XM; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; Institute for Biomedical Informatics, University of Pennsylvania, Philadelphia, PA, USA.
Best A; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; Carisma Therapeutics, Philadelphia, PA, USA.
Zeeman M; Carisma Therapeutics, Philadelphia, PA, USA.
Schmierer M; Carisma Therapeutics, Philadelphia, PA, USA.
Gabrusiewicz K; Carisma Therapeutics, Philadelphia, PA, USA.
Anderson NR; Carisma Therapeutics, Philadelphia, PA, USA.
Petty NE; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Cummins KD; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Shen F; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Shan X; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Veliz K; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Blouch K; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Yashiro-Ohtani Y; Carisma Therapeutics, Philadelphia, PA, USA.
Kenderian SS; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Kim MY; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; Department of Medicine, Oncology Division, Washington University School of Medicine, St. Louis, MO, USA.
O'Connor RS; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Wallace SR; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Kozlowski MS; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Marchione DM; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Shestov M; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Garcia BA; Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
June CH; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Gill S; Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. .; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. .; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. .
Pokaż więcej
Źródło :
Nature biotechnology [Nat Biotechnol] 2020 Aug; Vol. 38 (8), pp. 947-953. Date of Electronic Publication: 2020 Mar 23.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Adoptive*
Macrophages/*physiology
Neoplasms/*therapy
Animals ; Cell Line, Tumor ; Cell Survival ; Humans ; Immunotherapy ; Lung Neoplasms/therapy ; Mice ; Microscopy, Video ; Neoplasms, Experimental
Czasopismo naukowe
Tytuł :
The evolution of interventional oncology in the 21st century.
Autorzy :
Helmberger T; Department of Radiology, Neuroradiology, and minimal-invasive Therapy, Munich Klinik Bogenhausen Englschalkingerstr. 77 81925, Munich, Germany.
Pokaż więcej
Źródło :
The British journal of radiology [Br J Radiol] 2020 Sep 01; Vol. 93 (1113), pp. 20200112. Date of Electronic Publication: 2020 Aug 14.
Typ publikacji :
Historical Article; Journal Article; Review
MeSH Terms :
Immunotherapy/*trends
Medical Oncology/*trends
Neoplasms/*therapy
Cancer Vaccines/therapeutic use ; Chemoembolization, Therapeutic/methods ; Chemoembolization, Therapeutic/trends ; History, 21st Century ; Humans ; Immunization, Passive/methods ; Immunomodulation ; Immunotherapy/methods ; Immunotherapy, Active/methods ; Neoplasms/immunology ; Radiation Oncology/trends ; Radiofrequency Ablation/methods ; Radiofrequency Ablation/trends ; Yttrium Radioisotopes/therapeutic use
Czasopismo naukowe
Tytuł :
Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19.
Autorzy :
Asnani M; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Hayer KE; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; DBHi Bioinformatics Group, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Naqvi AS; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; DBHi Bioinformatics Group, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Zheng S; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Yang SY; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Oldridge D; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Ibrahim F; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Maragkakis M; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.; Laboratory of Genetics and Genomics, National Institute on Aging, NIH, Baltimore, MD, USA.
Gazzara MR; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Black KL; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; Lonza Biologics, Portsmouth, NH, USA.
Bagashev A; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Taylor D; DBHi Bioinformatics Group, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Mourelatos Z; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Grupp SA; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Barrett D; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Maris JM; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Sotillo E; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Barash Y; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Thomas-Tikhonenko A; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA. .; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA. .; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Apr; Vol. 34 (4), pp. 1202-1207. Date of Electronic Publication: 2019 Oct 07.
Typ publikacji :
Letter; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Frameshift Mutation*
Immunotherapy, Adoptive*
Antigens, CD19/*genetics
Introns/*genetics
Leukemia/*genetics
Antigens, CD19/chemistry ; Antigens, CD19/immunology ; Humans ; Immunotherapy ; Leukemia/immunology ; Leukemia/pathology ; Leukemia/therapy ; Prognosis
Raport
Tytuł :
Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo.
Autorzy :
He X; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.; Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 310058 Hangzhou, Zhejiang, China.
Yin X; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.; Department of Radiation Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, 310003 Hangzhou, Zhejiang, China.
Wu J; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Wickström SL; Department of Oncology and Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Duo Y; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Du Q; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.; Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, 510080 Guangzhou, China.
Qin S; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.; Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, 510080 Guangzhou, China.
Yao S; Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, 510080 Guangzhou, China.
Jing X; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Hosaka K; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Wu J; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
Jensen LD; Division of Cardiovascular Medicine, Department of Medical and Health Sciences, Linkoping University, 581 83 Linkoping, Sweden.
Lundqvist A; Department of Oncology and Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Salter AI; Center and Department of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.
Bräutigam L; Comparative Medicine, Karolinska Institutet, SE-17177 Stockholm, Sweden.
Tao W; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Chen Y; Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University, 250012 Jinan, Shandong, China.
Kiessling R; Department of Oncology and Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Cao Y; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden; .
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Sep 15; Vol. 117 (37), pp. 22910-22919. Date of Electronic Publication: 2020 Aug 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy/*methods
Lymphocytes, Tumor-Infiltrating/*metabolism
Single-Cell Analysis/*methods
Animals ; Cell Line, Tumor ; Cytotoxicity, Immunologic/immunology ; Immunotherapy, Adoptive/methods ; Lymphocyte Activation/physiology ; Models, Animal ; Neoplasm Metastasis/pathology ; Neoplasms/metabolism ; Receptors, Antigen, T-Cell/immunology ; T-Lymphocytes/immunology ; Xenograft Model Antitumor Assays/methods ; Zebrafish
Czasopismo naukowe
Tytuł :
Immunotherapy in Gastrointestinal Malignancies.
Autorzy :
Mizrahi J; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pant S; Investigational Cancer Therapeutics, The University of Texas MD Anderson Center, Houston, TX, USA. .
Pokaż więcej
Źródło :
Advances in experimental medicine and biology [Adv Exp Med Biol] 2020; Vol. 1244, pp. 93-106.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy*
Gastrointestinal Neoplasms/*immunology
Gastrointestinal Neoplasms/*therapy
Humans ; Immunotherapy, Adoptive ; Programmed Cell Death 1 Receptor/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
[Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Autorzy :
Qian L; Bone Marrow Transplantation Center of the First Affiliated Hospital, and Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China.
Chen J; Bone Marrow Transplantation Center of the First Affiliated Hospital, and Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China.
Wu X; Bone Marrow Transplantation Center of the First Affiliated Hospital, and Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China.
Jing R; Bone Marrow Transplantation Center of the First Affiliated Hospital, and Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China.
Sun J; Bone Marrow Transplantation Center of the First Affiliated Hospital, and Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China.; Institute of Hematology, Zhejiang University & Laboratory of Stem Cell and Immunotherapy Engineering, Hangzhou 310058, Zhejiang, China.
Pokaż więcej
Źródło :
Sheng wu gong cheng xue bao = Chinese journal of biotechnology [Sheng Wu Gong Cheng Xue Bao] 2019 Dec 25; Vol. 35 (12), pp. 2339-2349.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cell- and Tissue-Based Therapy*
Immunotherapy, Adoptive*
Child ; Humans ; Immunotherapy ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen ; T-Lymphocytes
Czasopismo naukowe
Tytuł :
Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives.
Autorzy :
Abdul-Latif M; Department of Oncology, North Middlesex University Hospital, Sterling Way, London N18 1QX, United Kingdom.
Townsend K; The Royal Marsden, Fulham Road, London SW3 6JJ, United Kingdom.
Dearman C; The Royal Marsden, Fulham Road, London SW3 6JJ, United Kingdom.
Shiu KK; Department of Medical Oncology, University College London Cancer Institute, 72 Huntly St., Fitzrovia, London WC1E 6AG, United Kingdom.
Khan K; Department of Oncology, North Middlesex University Hospital, Sterling Way, London N18 1QX, United Kingdom; Department of Medical Oncology, University College London Cancer Institute, 72 Huntly St., Fitzrovia, London WC1E 6AG, United Kingdom. Electronic address: .
Pokaż więcej
Źródło :
Cancer treatment reviews [Cancer Treat Rev] 2020 Aug; Vol. 88, pp. 102030. Date of Electronic Publication: 2020 May 28.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Gastrointestinal Neoplasms/*therapy
Immunotherapy/*methods
Animals ; Antineoplastic Agents, Immunological/administration & dosage ; Cancer Vaccines/administration & dosage ; Gastrointestinal Neoplasms/immunology ; Humans ; Immunotherapy, Adoptive/methods ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
[Immunotherapies of cancer: Is there any impact on patient cognitive functions?]
Autorzy :
Castel H; Normandie Univ, UniRouen, Inserm U1239, DC2N, Institut de recherche et d'innovation en biomédecine (IRIB), 25 rue Tesnière, 76000 Rouen, France - Plate-forme Cancer et cognition, Ligue nationale contre le cancer, 14000 Caen, France.
Joly F; Plate-forme Cancer et cognition, Ligue nationale contre le cancer, 14000 Caen, France - Département d'oncologie médicale, Centre François Baclesse, 14000 Caen, France - Normandie Univ, UniCaen, Inserm U1086, Anticipe, 14000 Caen, France - CHU de Caen, 14000 Caen, France.
Pokaż więcej
Transliterated Title :
Immunothérapies du cancer : quel impact sur les fonctions cognitives ?
Źródło :
Medecine sciences : M/S [Med Sci (Paris)] 2020 Aug-Sep; Vol. 36 (8-9), pp. 695-699. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :
Wiadomości
MeSH Terms :
Antineoplastic Agents, Immunological/*adverse effects
Cancer Vaccines/*pharmacology
Cognition/*drug effects
Immunotherapy/*adverse effects
Neoplasms/*therapy
Animals ; Brain/drug effects ; Brain/physiology ; Cancer Vaccines/therapeutic use ; Cell Cycle Checkpoints/drug effects ; Cognition/physiology ; Humans ; Immunotherapy/methods ; Immunotherapy, Adoptive/adverse effects ; Neoplasms/immunology ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/immunology ; Receptors, Chimeric Antigen/metabolism ; T-Lymphocytes/physiology
Periodyk
Tytuł :
[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management].
Autorzy :
Basse C; Institut du thorax Curie Montsouris, institut Curie, Paris, France.
Swalduz A; Centre Léon-Bérard, département d'oncologie médicale, Lyon, France.
Levra MG; CHU de Grenoble-Alpes, oncologie thoracique SHUPP, CS10217 cedex, 38043 Grenoble, France; Hospital HM Delfos, HM Hospitales, Centro Integral Oncológico Clara-Campal (HM-CIOCC), Department of Medical Oncology, Barcelona, Espagne; Université Grenoble-Alpes, Institute for Advanced Biosciences, Inserm U1209 CNRS UMR5309, Grenoble, France.
Girard N; Institut du thorax Curie Montsouris, institut Curie, Paris, France.
Remon J; Hospital HM Delfos, HM Hospitales, Centro Integral Oncológico Clara-Campal (HM-CIOCC), Department of Medical Oncology, Barcelona, Espagne.
Moro-Sibilot D; CHU de Grenoble-Alpes, oncologie thoracique SHUPP, CS10217 cedex, 38043 Grenoble, France. Electronic address: .
Pokaż więcej
Transliterated Title :
Immunothérapie des cancers bronchiques non à petites cellules métastatiques, de la première ligne à la résistance et sa prise en charge.
Źródło :
Bulletin du cancer [Bull Cancer] 2020 Jul - Aug; Vol. 107 (7-8), pp. 779-791. Date of Electronic Publication: 2020 Jun 10.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*therapy
Immunotherapy/*methods
Lung Neoplasms/*therapy
Anaplastic Lymphoma Kinase/genetics ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Clinical Trials, Phase III as Topic ; Combined Modality Therapy/methods ; Disease Progression ; Drug Resistance, Neoplasm/physiology ; Genes, erbB-1 ; Humans ; Immunotherapy, Adoptive/methods ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Mutation ; Receptors, Chimeric Antigen/therapeutic use ; Translocation, Genetic
Czasopismo naukowe
Tytuł :
Immunotherapy-related adverse effects on F-FDG PET/CT imaging.
Autorzy :
Gandy N; Paul Strickland Scanner Centre, Northwood, England.
Arshad MA; Imaging Department, Imperial College Healthcare NHS Trust, London, United Kingdom.
Wallitt KL; Paul Strickland Scanner Centre, Northwood, England.; Imaging Department, Imperial College Healthcare NHS Trust, London, United Kingdom.
Dubash S; Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London, United Kingdom.; Department of Surgery and Cancer, Imperial College, London, United Kingdom.
Khan S; Imaging Department, Imperial College Healthcare NHS Trust, London, United Kingdom.
Barwick TD; Imaging Department, Imperial College Healthcare NHS Trust, London, United Kingdom.; Department of Surgery and Cancer, Imperial College, London, United Kingdom.
Pokaż więcej
Źródło :
The British journal of radiology [Br J Radiol] 2020 Jul; Vol. 93 (1111), pp. 20190832. Date of Electronic Publication: 2020 Feb 27.
Typ publikacji :
Journal Article
MeSH Terms :
Fluorodeoxyglucose F18*
Radiopharmaceuticals*
Antineoplastic Agents, Immunological/*adverse effects
Immunotherapy/*adverse effects
Neoplasms/*therapy
Positron Emission Tomography Computed Tomography/*methods
Aged ; Aged, 80 and over ; B7-H1 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/antagonists & inhibitors ; Female ; Humans ; Immunotherapy, Adoptive/adverse effects ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Rituximab/adverse effects
Czasopismo naukowe
Tytuł :
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
Autorzy :
Nixon AB; Duke University School of Medicine, Department of Medicine/Medical Oncology, 133 Jones Building, Research Drive, Durham, NC, 27710, USA. .
Schalper KA; Yale School of Medicine, Translational Immuno-Oncology Laboratory, Yale Cancer Center, 333 Cedar St. FMP117, New Haven, CT, 06520-8023, USA.
Jacobs I; Pfizer Inc, Early Oncology Development and Clinical Research, 219 East 42nd St, New York, NY, 10017-5755, USA.
Potluri S; Pfizer Inc., Computational Biology, 230 E Grand Ave, South San Francisco, CA, 94080, USA.
Wang IM; Pfizer Inc., 10777 Science Center Dr., San Diego, CA, 92121, USA.
Fleener C; Pfizer Inc., Translational Oncology, La Jolla, CA, USA.; Present Address: Translational Science at Samumed, LLC, La Jolla, CA, USA.
Pokaż więcej
Źródło :
Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Nov 27; Vol. 7 (1), pp. 325. Date of Electronic Publication: 2019 Nov 27.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms :
Biomarkers, Tumor*
Immunity*
Immunotherapy*
Molecular Targeted Therapy*
Neoplasms/*etiology
Neoplasms/*therapy
Animals ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Cancer Vaccines/immunology ; Cancer Vaccines/therapeutic use ; Humans ; Immunotherapy, Adoptive ; Neoplasms/metabolism ; Neoplasms/pathology ; Treatment Outcome ; Tumor Microenvironment/genetics ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
T-cell therapies for T-cell lymphoma.
Autorzy :
Toner K; Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA.
Bollard CM; Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; The George Washington School of Medicine and Health Sciences, Washington, DC, USA.
Dave H; Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; The George Washington School of Medicine and Health Sciences, Washington, DC, USA. Electronic address: .
Pokaż więcej
Źródło :
Cytotherapy [Cytotherapy] 2019 Sep; Vol. 21 (9), pp. 935-942. Date of Electronic Publication: 2019 Jul 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy*
Lymphoma, T-Cell/*therapy
T-Lymphocytes/*immunology
Animals ; Clinical Trials as Topic ; Humans ; Immunologic Factors/therapeutic use ; Immunotherapy, Adoptive
Czasopismo naukowe
Tytuł :
Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments.
Autorzy :
Sivanand A; 1 Division of Dermatology, University of Alberta, Edmonton, AB, Canada.
Surmanowicz P; 1 Division of Dermatology, University of Alberta, Edmonton, AB, Canada.
Alhusayen R; 2 Division of Dermatology, University of Toronto, ON, Canada.
Hull P; 3 Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, NS, Canada.
Litvinov IV; 4 Division of Dermatology, McGill University, Montreal, QC, Canada.
Zhou Y; 5 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
Gniadecki R; 1 Division of Dermatology, University of Alberta, Edmonton, AB, Canada.
Pokaż więcej
Źródło :
Journal of cutaneous medicine and surgery [J Cutan Med Surg] 2019 Sep/Oct; Vol. 23 (5), pp. 537-544. Date of Electronic Publication: 2019 Jul 29.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy*
Antineoplastic Agents, Immunological/*therapeutic use
Mycosis Fungoides/*therapy
Sezary Syndrome/*therapy
Skin Neoplasms/*therapy
Antibodies, Monoclonal, Humanized/therapeutic use ; Cancer Vaccines/therapeutic use ; Humans ; Immunotherapy, Adoptive ; Interferons/therapeutic use ; Mycosis Fungoides/immunology ; Nivolumab/therapeutic use ; Photopheresis ; Sezary Syndrome/immunology ; Skin Neoplasms/immunology
Czasopismo naukowe
Tytuł :
[Current advances in immunotherapy in ovarian cancer].
Autorzy :
Le Saux O; Hospices civils de Lyon, service d'oncologie médicale, 165, chemin du grand Revoyet, 69495 Pierre-Bénite, France; Université Claude-Bernard Lyon I, centre de recherche en cancérologie de Lyon, CNRS 5286, centre Léon-Bérard, Inserm 1052, 69008 Lyon, France. Electronic address: .
Dubois B; Université Claude-Bernard Lyon I, centre de recherche en cancérologie de Lyon, CNRS 5286, centre Léon-Bérard, Inserm 1052, 69008 Lyon, France.
Stern MH; Université de recherche PSL, institut Curie, DNA repair and uveal melanoma (D.R.U.M.), équipe labellisée par la Ligue nationale contre le cancer, Inserm U830, 75248 Paris, France; Institut Curie, département de biologie des tumeurs, Paris, France.
Terme M; PARCC (Paris-Cardiovascular Research Center), Inserm U970, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, faculté de médecine, Paris, France.
Tartour E; PARCC (Paris-Cardiovascular Research Center), Inserm U970, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, faculté de médecine, Paris, France; AP-HP, Hôpital Européen Georges-Pompidou, service d'immunologie biologique, Paris, France.
Classe JM; Institut de cancérologie de l'Ouest, Saint-Herblain, départment de chirurgie carcinologique, Loire Atlantique, France.
Chopin N; Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.
Trédan O; Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.
Caux C; Université Claude-Bernard Lyon I, centre de recherche en cancérologie de Lyon, CNRS 5286, centre Léon-Bérard, Inserm 1052, 69008 Lyon, France.
Ray-Coquard I; Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.
Pokaż więcej
Transliterated Title :
Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire.
Źródło :
Bulletin du cancer [Bull Cancer] 2020 Apr; Vol. 107 (4), pp. 465-473. Date of Electronic Publication: 2020 Feb 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy/*methods
Ovarian Neoplasms/*drug therapy
Antigens, Neoplasm ; Antineoplastic Agents, Immunological/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/antagonists & inhibitors ; Female ; Humans ; Immunotherapy/trends ; Immunotherapy, Adoptive/methods ; Immunotherapy, Adoptive/trends ; Ovarian Neoplasms/immunology
Czasopismo naukowe
Tytuł :
Immune-Based Therapies in Acute Leukemia.
Autorzy :
Witkowski MT; Department of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA. Electronic address: .
Lasry A; Department of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Carroll WL; Department of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA; Department of Pediatrics, New York University School of Medicine, New York, NY 10016, USA.
Aifantis I; Department of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Pokaż więcej
Źródło :
Trends in cancer [Trends Cancer] 2019 Oct; Vol. 5 (10), pp. 604-618. Date of Electronic Publication: 2019 Aug 29.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunity*
Immunotherapy*/methods
Antineoplastic Agents, Immunological/*therapeutic use
Leukemia, Myeloid, Acute/*immunology
Leukemia, Myeloid, Acute/*therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Animals ; Antineoplastic Agents, Immunological/pharmacology ; Disease Susceptibility ; Humans ; Immunotherapy, Adoptive ; Leukemia, Myeloid, Acute/pathology ; Molecular Targeted Therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Receptors, Antigen, T-Cell/metabolism ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Autorzy :
Xu X; College of Computer Science and Software Engineering, Shenzhen University, Shenzhen, China.; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
Li J; College of Computer Science and Software Engineering, Shenzhen University, Shenzhen, China.
Zou J; University of Toronto, Toronto, Ontario, Canada.
Feng X; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.; Department of Biomedical Informatics, School of Basic Medical Sciences, MOE Key Lab of Cardiovascular Sciences, Peking University, Beijing, China.
Zhang C; School of Mathematical Sciences, Dalian University of Technology, Dalian, China.
Zheng R; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.; School of Computer Science and Engineering, Central South University, Changsha, China.
Duanmu W; School of Mathematical Sciences, Dalian University of Technology, Dalian, China.
Saha-Mandal A; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.
Ming Z; College of Computer Science and Software Engineering, Shenzhen University, Shenzhen, China.
Wang E; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.; Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Department of Medicine, McGill University, Montreal, Quebec, Canada.
Pokaż więcej
Źródło :
JAMA network open [JAMA Netw Open] 2019 Sep 04; Vol. 2 (9), pp. e199292. Date of Electronic Publication: 2019 Sep 04.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy*
Disease Susceptibility/*immunology
Killer Cells, Natural/*immunology
Killer Cells, Natural/*metabolism
Lymphocytes, Tumor-Infiltrating/*immunology
Neoplasms/*immunology
Tumor Microenvironment/*immunology
Female ; Gene Expression Regulation, Neoplastic ; Genetic Association Studies ; Humans ; Immunotherapy, Adoptive ; Lymphocyte Activation/immunology ; Male ; Neoplasms/physiopathology ; Observational Studies as Topic ; Prognosis ; Sequence Analysis, RNA
Czasopismo naukowe
Tytuł :
Revisiting Immunotherapy: A Focus on Prostate Cancer.
Autorzy :
Cha HR; Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama.; McWhorter School of Pharmacy, Samford University, Birmingham, Alabama.
Lee JH; Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama.; PharmAbcine Inc., Yuseong-gu Daejeon, Republic of Korea.
Ponnazhagan S; Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2020 Apr 15; Vol. 80 (8), pp. 1615-1623. Date of Electronic Publication: 2020 Feb 17.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy/*methods
Prostatic Neoplasms/*therapy
Androgen Receptor Antagonists/therapeutic use ; Antibodies, Bispecific/therapeutic use ; Antineoplastic Agents/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/antagonists & inhibitors ; Combined Modality Therapy/methods ; Forecasting ; Humans ; Immunization, Passive/methods ; Immunotherapy/trends ; Immunotherapy, Active/methods ; Male ; Neoplastic Stem Cells/immunology ; Precision Medicine/methods ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Prostatic Neoplasms/etiology ; Prostatic Neoplasms/immunology ; Prostatic Neoplasms, Castration-Resistant/immunology ; Prostatic Neoplasms, Castration-Resistant/therapy ; Prostatitis/complications
Czasopismo naukowe
Tytuł :
New emerging targets in cancer immunotherapy: the role of neoantigens.
Autorzy :
De Mattos-Arruda L; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol University Hospital, Badalona, Spain .; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
Blanco-Heredia J; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol University Hospital, Badalona, Spain.; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
Aguilar-Gurrieri C; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol University Hospital, Badalona, Spain.
Carrillo J; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol University Hospital, Badalona, Spain.; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
Blanco J; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol University Hospital, Badalona, Spain.; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.; Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Vic, Spain.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2020 Apr; Vol. 4 (Suppl 3).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy/*methods
Neoplasms/*therapy
Antigens, Neoplasm/immunology ; Cancer Vaccines/administration & dosage ; Cancer Vaccines/immunology ; Humans ; Immunotherapy, Adoptive ; Molecular Targeted Therapy ; Neoplasms/immunology
Czasopismo naukowe
Tytuł :
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.
Autorzy :
Itzhaki O; Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Jacoby E; Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Nissani A; Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Levi M; Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Nagler A; Department of Bone Marrow Transplantation, Sheba Medical Center, Tel Hashomer, Israel.
Kubi A; Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Brezinger K; Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Brayer H; Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Zeltzer LA; Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Rozenbaum M; Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Vernitsky H; Hematology Laboratory, Sheba Medical Center, Tel Hashomer, Israel.
Markel G; Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel.; Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Toren A; Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Avigdor A; Department of Bone Marrow Transplantation, Sheba Medical Center, Tel Hashomer, Israel.
Schachter J; Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Besser MJ; Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel .; Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Wohl Institute for Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel.
Pokaż więcej
Źródło :
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Mar; Vol. 8 (1).
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD19/*immunology
Immunotherapy, Adoptive/*methods
Leukocytes, Mononuclear/*immunology
Lymphoma, Non-Hodgkin/*therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Receptors, Chimeric Antigen/*immunology
Adolescent ; Adult ; Age Factors ; Antigens, CD19/genetics ; Antigens, CD19/metabolism ; Drug Resistance, Neoplasm ; Female ; Humans ; Immunotherapy/methods ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphoma, Non-Hodgkin/immunology ; Lymphoma, Non-Hodgkin/pathology ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Receptors, Chimeric Antigen/genetics ; Treatment Outcome ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies